News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,241 Results
Type
Article (2581)
Company Profile (46)
Press Release (37613)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14220)
Career Advice (78)
Deals (2110)
Drug Delivery (9)
Drug Development (4159)
Employer Resources (10)
FDA (449)
Job Trends (804)
News (20329)
Policy (1066)
Tag
Academia (144)
Allergies (7)
Alliances (3493)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (27)
Approvals (452)
Artificial intelligence (31)
Autoimmune disease (9)
Automation (2)
Bankruptcy (12)
Best Places to Work (498)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (30)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (44)
Cancer (327)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (33)
CDC (1)
Cell therapy (84)
Cervical cancer (2)
Clinical research (3456)
Collaboration (202)
Company closure (2)
Compensation (105)
COVID-19 (185)
CRISPR (11)
C-suite (114)
Cystic fibrosis (7)
Data (425)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (492)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (44)
Earnings (4541)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (6429)
Executive appointments (135)
FDA (596)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (168)
Gene editing (32)
Generative AI (1)
Gene therapy (58)
GLP-1 (63)
Government (161)
Guidances (24)
Healthcare (709)
HIV (2)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (5)
Infectious disease (198)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (26)
Interviews (7)
IPO (1002)
IRA (7)
Job creations (293)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (216)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (318)
Medtech (319)
Mergers & acquisitions (1226)
Metabolic disorders (72)
Multiple sclerosis (23)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (167)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (18)
Pain (25)
Pancreatic cancer (22)
Parkinson's disease (12)
Partnered (4)
Patents (53)
Patient recruitment (28)
Peanut (1)
People (5880)
Pharmaceutical (5)
Phase 1 (1477)
Phase 2 (1712)
Phase 3 (923)
Pipeline (408)
Policy (16)
Postmarket research (30)
Preclinical (640)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (15)
Rare diseases (63)
Real estate (426)
Recruiting (5)
Regulatory (925)
Reports (7)
Research institute (149)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (21)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (497)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Today (1)
Last 7 days (42)
Last 30 days (153)
Last 365 days (2435)
2026 (265)
2025 (2438)
2024 (2619)
2023 (2873)
2022 (3780)
2021 (4058)
2020 (3478)
2019 (2067)
2018 (1557)
2017 (1797)
2016 (1626)
2015 (1835)
2014 (1369)
2013 (1189)
2012 (1400)
2011 (1334)
2010 (1182)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1954)
Australia (307)
California (1616)
Canada (249)
China (81)
Colorado (55)
Connecticut (16)
Delaware (5)
Europe (4034)
Florida (65)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (3)
Indiana (61)
Japan (18)
Kansas (14)
Kentucky (1)
Maryland (49)
Massachusetts (576)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (137)
New York (81)
North Carolina (133)
Northern California (790)
Ohio (45)
Oklahoma (2)
Oregon (6)
Pennsylvania (113)
Puerto Rico (1)
Rhode Island (3)
South America (40)
South Carolina (1)
Southern California (658)
Tennessee (5)
Texas (153)
United States (3245)
Utah (5)
Virginia (12)
Washington D.C. (3)
Washington State (97)
West Virginia (1)
Wisconsin (13)
40,241 Results for "selecta biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Selecta Biosciences, Inc. (NASDAQ: SELB) (the Company) today announced that it has merged with Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.
November 13, 2023
·
15 min read
Business
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Selecta Biosciences, Inc. today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
May 4, 2023
·
12 min read
Genetown
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
Selecta Biosciences, Inc. today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.
February 7, 2023
·
1 min read
Genetown
Selecta Biosciences Provides Business Update and Outlook for 2023
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today provided a corporate update, including its roadmap for 2023.
January 9, 2023
·
9 min read
Business
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Selecta Biosciences, Inc. and Astellas Pharma Inc. today announced an exclusive licensing and development agreement for IdeXork (Xork).
January 9, 2023
·
10 min read
Genetown
Selecta Biosciences to Participate in Upcoming September 2022 Investor Conferences
Selecta Biosciences, Inc.announced that Company’s Management will participate in upcoming investor conferences in September.
September 12, 2022
·
1 min read
Business
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
August 17, 2023
·
13 min read
Genetown
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences, Inc. announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB . As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212.
October 31, 2023
·
6 min read
Business
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that it plans to host a conference call on Thursday, May 4, 2023, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2023 and provide a business update.
April 28, 2023
·
1 min read
Business
Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Selecta Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a business update.
November 3, 2022
·
14 min read
1 of 4,025
Next
